Eligible conditions include: Diffuse large B-cell lymphoma High-grade ... with 5-year survival rates dropping to around 30%. CAR T-cell therapy is a personalised treatment where a patient ...

The survival rate of non-Hodgkin’s lymphoma is generally lower than that of Hodgkin’s lymphoma, but it’s still often curable. Lymphoma is a group of cancers that start in the lymphatic system.

T-cell lymphoma is a type of lymphatic cancer that starts in the T lymphocytes (T cells), a type of white blood cell. T lymphocytes (T cells) and B lymphocytes (B cells) are two types of white ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome: Marseille, France Tuesday, February 18, 2025, 12:00 Hrs ...

Innate Pharma has secured US Food and Drug Administration (FDA) breakthrough therapy designation for lacutamab to treat adults with relapsed or refractory Sézary syndrome. Lacutamab is a ...

CAR T-cell therapy showed efficacy in relapsed large B-cell lymphoma across age groups, including patients 70 and 80 years or older.

Overall survival was significantly improved ... of certain types of classical Hodgkin lymphoma, anaplastic large cell lymphoma and peripheral T-cell lymphoma.

Odronextamab demonstrated a manageable safety profile and generated durable responses in patients with R/R DLBCL who have ...